Abstract
Management of acute and chronic pain has always been a key area of clinical research. Enkephalinase inhibitors (EIs) seem to be promising as therapeutic agents having antinociceptive action. They additionally possess anticraving, antidiarrhoeal and antidepressant actions. The antinociceptive action of EIs has been reported for over a decade however, their therapeutic potential is yet to be effectively explored. EIs may be broadly classified as endogenous and those that are obtained synthetically. Endogenous EIs include peptides like spinorphin and opiorphin. And compounds like RB 101, RB 120, RB 3007 constitute the synthetically obtained EIs. Endogenous and synthetic inhibitors enkephalin degrading enzymes have been studied in vivo using standard animal models. The potential EI targets appear to be APN (Aminopeptidase N), NEP (Neutral endopeptidase), DPP-III (Dipeptidyl peptidase). EIs possess the advantage that they lack the opioid side effects. This article reviews the mechanisms by which EIs act and elucidates the pathways involved.
Keywords: Enkephalinase inhibitors, antinociception, pain
Current Drug Targets
Title: Enkephalinase Inhibitors: Potential Agents for the Management of Pain
Volume: 9 Issue: 10
Author(s): V. Thanawala, V. J. Kadam and R. Ghosh
Affiliation:
Keywords: Enkephalinase inhibitors, antinociception, pain
Abstract: Management of acute and chronic pain has always been a key area of clinical research. Enkephalinase inhibitors (EIs) seem to be promising as therapeutic agents having antinociceptive action. They additionally possess anticraving, antidiarrhoeal and antidepressant actions. The antinociceptive action of EIs has been reported for over a decade however, their therapeutic potential is yet to be effectively explored. EIs may be broadly classified as endogenous and those that are obtained synthetically. Endogenous EIs include peptides like spinorphin and opiorphin. And compounds like RB 101, RB 120, RB 3007 constitute the synthetically obtained EIs. Endogenous and synthetic inhibitors enkephalin degrading enzymes have been studied in vivo using standard animal models. The potential EI targets appear to be APN (Aminopeptidase N), NEP (Neutral endopeptidase), DPP-III (Dipeptidyl peptidase). EIs possess the advantage that they lack the opioid side effects. This article reviews the mechanisms by which EIs act and elucidates the pathways involved.
Export Options
About this article
Cite this article as:
Thanawala V., Kadam J. V. and Ghosh R., Enkephalinase Inhibitors: Potential Agents for the Management of Pain, Current Drug Targets 2008; 9 (10) . https://dx.doi.org/10.2174/138945008785909356
DOI https://dx.doi.org/10.2174/138945008785909356 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IL-6, IL-1β, and MDA Correlate with Thrombolysis in Myocardial Infarction
(TIMI) Risk Score in Patients with Acute Coronary Syndrome
Recent Advances in Inflammation & Allergy Drug Discovery Therapeutic Potential of Plant Extracts and Phytochemicals Against Brain Ischemia-Reperfusion Injury: A Review
The Natural Products Journal Non-Invasive Approaches to Visualize the Endothelin Axis In Vivo Using State-of-the-Art Molecular Imaging Modalities
Mini-Reviews in Medicinal Chemistry Effects Of Glycoprotein IIb/IIIa Antagonists: Anti Platelet Aggregation And Beyond
Current Drug Metabolism Modulation of PMN-Endothelial Cells Interactions by Cyclic Nucleotides
Current Pharmaceutical Design Catastrophic Antiphospholipid Syndrome: Lessons from the “CAPS Registry”
Current Rheumatology Reviews The Antiplatelet Drug Target in Atherosclerotic Diseases
Cardiovascular & Hematological Disorders-Drug Targets Proteinase-Activated Receptor 2 (PAR2): A Challenging New Target for Treatment of Vascular Diseases
Current Pharmaceutical Design The Role of Intravenous Dihydropyridine Calcium Channel Blockers in the Perioperative Management of Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology Blood Pressure Management in Acute Stroke
Current Hypertension Reviews Plasticity and Maintenance of Hematopoietic Stem Cells During Development
Recent Patents on Biotechnology Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Growth Factor Therapy in Atherosclerotic Disease-Friend or Foe
Current Pharmaceutical Design Identification of a Novel Intestinal First Pass Metabolic Pathway: NQO1 Mediated Quinone Reduction and Subsequent Glucuronidation
Current Drug Metabolism Ubiquitin and ubiquitin-like proteins in cardiac disease and protection
Current Drug Targets Biochemical Basis of Ischemic Heart Injury and of Cardioprotective Interventions
Current Medicinal Chemistry Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets
Current Pharmaceutical Design Recent Advances in Ethnopharmacological and Toxicological Properties of Bioactive Compounds from <i>Aloe barbadensis</i> (Miller), <i>Aloe vera</i>
Current Bioactive Compounds Update on the Role of Neutrophils in Atherosclerotic Plaque Vulnerability
Current Drug Targets Oxygen Sensing, Cardiac Ischemia, HIF-1α and Some Emerging Concepts
Current Cardiology Reviews